ProCE Banner Activity

GRIFFIN Update: Phase II Study of Daratumumab + VRd vs VRd Alone for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

Slideset Download
Conference Coverage
The addition of daratumumab to VRd in transplant-eligible patients with MM led to significant improvement in response that deepened over time vs VRd alone.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company